Prevention and treatment of influenza in high-risk groups: Children, pregnant women, immunocompromised hosts, and nursing home residents

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 2, 2006, Pages

  Whitley, Richard J ^a   Monto, Arnold S ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; LIVE VACCINE; OSELTAMIVIR; PLACEBO; SIALIDASE INHIBITOR; TRIPLE VACCINE; ZANAMIVIR;

ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BORDETELLA PERTUSSIS; CHILD HEALTH CARE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG APPROVAL; DRUG INDICATION; EPIDEMIOLOGICAL DATA; HEALTH PROGRAM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VACCINATION; JAPAN; MORTALITY; NEUROTOXICITY; NONHUMAN; NURSING HOME PATIENT; OTITIS MEDIA; POPULATION RESEARCH; PREGNANT WOMAN; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RAT; REMISSION; REVIEW; TREATMENT INDICATION; UNITED STATES; VIRUS RESISTANCE;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE OUTBREAKS; ENZYME INHIBITORS; FEMALE; HOMES FOR THE AGED; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; LEUKEMIA; MIDDLE AGED; NURSING HOMES; OSELTAMIVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RATS; RISK; UNITED STATES; VACCINATION; ZANAMIVIR;

EID: 33750285513     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/507548     Document Type: Review

References (27)

1. Munoz FM. The impact of influenza in children. Semin Pediatr Infect Dis 2002; 13:72-7.
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005; 54(RR08):1-40.
3. Centers for Disease Control and Prevention. Estimated influenza vaccination coverage among adults and children-United States, September 1, 2004-January 31, 2005. MMWR Morb Mortal Wkly Rep 2005; 54: 304-7.
4. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003; 36:299-305.
5. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35:512-7.
6. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 200-2004. N Engl J Med 2005; 353:2559-67.
7. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006; 194:5111-8 (in this supplement).
8. MedImmune. Preliminary data from CAIV-T pivotal phase 3 trial demonstrate clinical efficacy over flu shot in head-to-head influenza study. Press release, 12 December 2005. Available at: http://phx.corporate-ir.net/ phoenix.zhtml?c=83037&p=irol-newsArticle&ID=794727&highlight =. Accessed 12 April 2006.
9. Roche Laboratories. Tamiflu (oseltamivir phosphate) capsules [product infomation]. Nutley, NJ: Roche Laboratories, 2000.
10. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33
11. [erratum: Pediatr Infect Dis J 2001; 20:421].
12. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
13. Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3:229-36.
14. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998; 148:1094-102.
15. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355-67.
16. La Rosa AM, Malik S, Englund JA, et al. Influenza A in hospitalized adults with leukemia and hematopoietic stem cell transplant (HSCT) recipients: risk factors for progression to pneumonia [abstract 418]. In: Program and abstracts of the 38th Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2001.
17. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-6.
18. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-24.
19. Machado CM, Boas LSV, Mendes AVA. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111-4.
20. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-4.
21. Goodman RA, Orenstein WA, Munrow F, Smith SC, Sikes RK. Impact of influenza A in a nursing home. JAMA 1982; 247:1451-2.
22. Budnick LD, Stricof RL, Ellis F. An outbreak of influenza in a nursing home, 1982. N Y State J Med 1984; 84:235-8.
23. Arden N, Monto AS, Ohmit SE. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. Am J Pub Health 1995; 85:399-401.
24. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. J Am Geriatr Soc 1999; 47:165-71.
25. Phair J, Kauffman CA, Bjornson A, et al. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med 1978; 92:822-8.
26. Peters PH, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49:1025-31.
27. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002; 50:608-16.